Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jan 2014
Multicenter Study Clinical TrialExpanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Vismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug Administration (FDA) approved for advanced basal cell carcinomas (BCCs) based on a single, nonrandomized, phase-II trial. Consequently, additional clinical data are critical to confirm the efficacy and safety of vismodegib. ⋯ This study provides important clinical data supporting the efficacy and safety of vismodegib. Larger studies are underway to assess predictors of response and long-term outcomes.
-
J. Am. Acad. Dermatol. · Oct 2013
Review Multicenter Study Meta Analysis Comparative StudyA systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris.
The ichthyoses comprise a group of inherited disorders of keratinization. Because of the need for lifelong treatment, it is important that therapies are beneficial, safe, and well tolerated. ⋯ Topical treatments including emollients, calcipotriol ointment, and liarozole cream seem to have therapeutic benefit and a good safety profile, although the use of topical calcipotriol is limited by a maximum weekly dose of 100 g. The advantage of oral liarozole over acitretin is uncertain. Multicenter trials comparing oral and topical interventions and evaluation of long-term outcomes are needed.
-
J. Am. Acad. Dermatol. · Oct 2013
Multicenter StudyCathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.
Excess cathelicidin and kallikrein 5 (KLK5) have been hypothesized to play a role in the pathophysiology of rosacea. ⋯ These results show that cathelicidin and KLK5 decrease in association with AZA exposure. Our observations suggest a new mechanism of action for AzA and that SPA may be a useful biomarker for disease activity.
-
J. Am. Acad. Dermatol. · Sep 2013
Randomized Controlled Trial Multicenter StudyA randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Few clinical trials have evaluated the combination of topical corticosteroids plus systemic therapies for psoriasis. ⋯ Addition of CP to etanercept yielded increased efficacy compared with etanercept alone at week 12 without an increase in treatment-related adverse events.
-
J. Am. Acad. Dermatol. · Sep 2010
Randomized Controlled Trial Multicenter Study Comparative StudyEfficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
The phase III randomized controlled evaluation of adalimumab every other week dosing in moderate to severe psoriasis trial (REVEAL) demonstrated adalimumab induced significant improvements and was well tolerated for patients with moderate to severe psoriasis. ⋯ Treatment of moderate to severe psoriasis with adalimumab led to consistent 75% or greater improvement in PASI score response rates across the majority of patient subgroups, with no significant differences in serious adverse events.